Australian Sea Anemone Venoms: Bioprospecting & Evolution. Australian sea anemones are a highly promising and largely unexplored source of peptides and proteins with potential therapeutic and diagnostic applications. This project aims to evaluate this potential by undertaking transcriptomic analyses of a number species of anemones from Australian waters and identifying peptides and proteins in their venoms by mass spectrometry. It will also demonstrate the value of transcriptomics in informing t ....Australian Sea Anemone Venoms: Bioprospecting & Evolution. Australian sea anemones are a highly promising and largely unexplored source of peptides and proteins with potential therapeutic and diagnostic applications. This project aims to evaluate this potential by undertaking transcriptomic analyses of a number species of anemones from Australian waters and identifying peptides and proteins in their venoms by mass spectrometry. It will also demonstrate the value of transcriptomics in informing taxonomic classification of anemones. In addition this project will assess toxin diversity within and between species based on nematocyst function from specific tissue sources and provide a clearer understanding of the evolution of venoms in Australian Actiniaria.Read moreRead less
Novel antimicrobial target discovery by an integrated approach. The project aims to uncover the molecular targets of BDM-I, a novel antimicrobial candidate discovered by the start-up Australian company BioDiem Ltd. BDM-I is active against many drug resistant bacterial and fungal microorganisms and it is currently in pre-clinical development. However, the lack of resistant phenotypes makes it difficult to identify BDM-I’s mechanism of action. The project plans to use an integrated approach that c ....Novel antimicrobial target discovery by an integrated approach. The project aims to uncover the molecular targets of BDM-I, a novel antimicrobial candidate discovered by the start-up Australian company BioDiem Ltd. BDM-I is active against many drug resistant bacterial and fungal microorganisms and it is currently in pre-clinical development. However, the lack of resistant phenotypes makes it difficult to identify BDM-I’s mechanism of action. The project plans to use an integrated approach that combines a novel technique of in silico screening with experimental validation. Project outcomes are anticipated to include the first computational method to integrate target and ligand similarity for proteome-scale target and off-target discovery, which will advance the global fight against drug-resistant microorganisms.Read moreRead less